Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study

British Journal of Clinical Pharmacology

Volumn 83, Issue 9, 2017, Pages 2077-2086

  Qian, Christina J ^a,b   Coulombe, Janie ^b   Suissa, Samy ^a,b   Ernst, Pierre ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

adverse events; asthma; cohort study; inhaled corticosteroids; pneumonia; quasi cohort

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; IPRATROPIUM BROMIDE; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEDOCROMIL; SHORT ACTING ANALGESIC AGENT; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; ANTIASTHMATIC AGENT; CORTICOSTEROID;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; ATELECTASIS; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY ANALYSIS; CHEMICALLY INDUCED; COMPLICATION; FACTUAL DATABASE; INHALATIONAL DRUG ADMINISTRATION; QUEBEC; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; CHILD; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FLUTICASONE; HUMANS; MALE; PNEUMONIA; QUEBEC; YOUNG ADULT;

EID: 85019020505     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13295     Document Type: Article

References (41)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44 (Database Issue): D1054–D1068.
2. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE, et al. The concise Guide to PHARMACOLOGY 2015/16: nuclear hormone receptors. Br J Pharmacol 2015; 172: 5956–5978.
3. Chapman KR. The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults. Clin Ther 2003; 25 (Suppl. C): C2–14.
4. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941–955.
5. Ernst P, Suissa S. Systemic effects of inhaled corticosteroids. Curr Opin Pulm Med 2012; 18: 85–89.
6. Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J 2014; 8: 59–65.
7. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001–1006.
8. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al., TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
9. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–166.
10. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029–1036.
11. O'Byrne PM, Pedersen S, Carlsson LG, Radner F, Thoren A, Peterson S, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183: 589–595.
12. Zhang L, Prietsch SO, Mendes AP, Von Groll A, Rocha GP, Carrion L, et al. Inhaled corticosteroids increase the risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma. Respirology 2013; 18: 272–277.
13. McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest 2013; 144: 1788–1794.
14. Pomey MP, Forest PG, Palley HA, Martin E. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States. Milbank Q 2007; 85: 469–498.
15. RAMQ. In: Prescription drug insurance – eligibility, ed Maladie Rdla. Quebec, Canada: Gouvernement du Québec, 2014.
16. Blais L, Beauchesne MF, Levesque S. Socioeconomic status and medication prescription patterns in pediatric asthma in Canada. J Adolesc Health 2006; 38: 607 e9–607 16.
17. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539–543.
18. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722–727.
19. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168–1174.
20. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–88.
21. Brassard P, Vutcovici M, Ernst P, Patenaude V, Sewitch M, Suissa S, et al. Increased incidence of inflammatory bowel disease in Quebec residents with airway diseases. Eur Respir J 2015; 45: 962–968.
22. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999–1009.
23. Blais L, Vilain A, Kettani FZ, Forget A, Lalonde G, Beauchesne MF, et al. Accuracy of the days' supply and the number of refills allowed recorded in Quebec prescription claims databases for inhaled corticosteroids. BMJ Open 2014; 4: e005903.
24. Blais L, Lemiere C, Menzies D, Berbiche D. Validity of asthma diagnoses recorded in the medical services database of Quebec. Pharmacoepidemiol Drug Saf 2006; 15: 245–252.
25. Lacasse Y, Montori VM, Lanthier C, Maltis F. The validity of diagnosing chronic obstructive pulmonary disease from a large administrative database. Can Respir J 2005; 12: 251–256.
26. Suissa S. The quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. Epidemiology 2015; 26: 242–246.
27. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian asthma Consensus report, 1999. Canadian Asthma Consensus Group CMAJ 1999; 161 (11 Suppl): S1–61.
28. National Heart Lung and Blood Institute. Guidelines for the diagnosis and management of asthma : expert panel report 2. Bethesda, MD: US Dept. of Health and Human Services, Public Health Service, National Heart, Lung, and Blood Institute, 1999.
29. Horwitz RI, Feinstein AR. The problem of ‘protopathic bias’ in case-control studies. Am J Med 1980; 68: 255–258.
30. Bansal V, Mangi MA, Johnson MM, Festic E. Inhaled corticosteroids and incident pneumonia in patients with asthma: systematic review and meta-analysis. Acta Med Acad 2015; 44: 135–158.
31. CDC. FastStats – pneumonia [online]. Center for Disease Prevention. Available at http://www.cdc.gov/nchs/fastats/pneumonia.htm (last accessed 15 May 2015).
32. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152 (4 Pt 1): 1316–1320.
33. Marin A, Monso E, Garcia-Nunez M, Sauleda J, Noguera A, Pons J, et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J 2010; 35: 295–302.
34. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; (3): CD010115.
35. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001; 107: 937–944.
36. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336.
37. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57: 880–884.
38. Meropol SB, Metlay JP. Accuracy of pneumonia hospital admissions in a primary care electronic medical record database. Pharmacoepidemiol Drug Saf 2012; 21: 659–665.
39. Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, et al. Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population. Int J Chron Obstruct Pulmon Dis 2015; 10: 1417–1425.
40. Cadieux G, Tamblyn R. Accuracy of physician billing claims for identifying acute respiratory infections in primary care. Health Serv Res 2008; 43: 2223–2238.
41. Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082–2090.